Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;41(7):202-207.
doi: 10.12788/fp.0490. Epub 2024 Jul 15.

Long-Term Assessment of Weight Loss Medications in a Veteran Population

Affiliations

Long-Term Assessment of Weight Loss Medications in a Veteran Population

Allison D Rodriguez et al. Fed Pract. 2024 Jul.

Abstract

Background: Overweight and obesity are common in the veteran population. Medical management with semaglutide, orlistat, liraglutide, phentermine, phentermine/topiramate, and naltrexone/bupropion is increasingly common. This study expands on a 2021 study and evaluates medication effectiveness.

Methods: This single-center retrospective study analyzed patients prescribed weight loss medications at Veteran Health Indiana. Primary outcomes included body weight loss and total weight loss with each medication at 3, 6, 12, 24, 36, and 48 months. Secondary outcomes were also used to determine the efficacy of the current weight loss medications.

Results: Of 105 included patients, 66 were treated with liraglutide, 30 with phentermine/topiramate, 5 with naltrexone/bupropion, 3 with orlistat, and 1 with phentermine. The absolute weight loss for all medications was 10.6 kg over the patient-specific duration of weight management therapy. The mean body weight loss was 9.2%. There were no statistically significant differences in primary or secondary outcomes between liraglutide and phentermine/topiramate. The group sizes were too small to analyze the other medication groups.

Conclusions: Patients in this study lost weight while using medications. However, there were no statistically significant differences among the medications. Patients did not receive uniformly consistent follow-up care, suggesting the need for more standardized processes that could lead to better weight loss outcomes.

PubMed Disclaimer

Conflict of interest statement

Author disclosures: The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.

Figures

FIGURE
FIGURE
Flow Diagram for Instances of Weight Loss Medication Use

References

    1. Overweight & obesity. Centers for Disease Control and Prevention; [Accessed April 23, 2024]. Updated September 21, 2023. https://www.cdc.gov/obesity/index.html .
    1. US Department of US Department Defense of Veterans Affairs. The Management of Adult Overweight and Obesity Working Group. VA/DoD Clinical Practice Guideline for the Management of Adult Overweight and Obesity. Updated July 2020. [Accessed April 23, 2024]. https://www.healthquality.va.gov/guidelines/CD/obesity/VADoDObesityCPGFi... .
    1. Health effects of overweight and obesity. Vol. 24. Centers for Disease Control and Prevention; Updated September: [Accessed April 23, 2024]. p. 2022. https://www.cdc.gov/healthyweight/effects/index.html .
    1. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023. doi: 10.1016/j.jacc.2013.11.004. - DOI - PubMed
    1. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362. doi: 10.1210/jc.2014-3415. - DOI - PubMed

LinkOut - more resources